Clinical Trial Update: Efficacy of iPSC-Derived Motor Neuron Cells (XS228) in Subacute Spinal Cord Injury: A Phase II Randomized Controlled Trial [Phase 2]

View source ↗

Summary

A Phase II randomized trial investigates XS228, an iPSC-derived motor neuron cell therapy, for subacute spinal cord injury; the study is currently not yet recru…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spinal Cord Injury

Drugs mentioned

• XS228

Snippet

Sponsor: XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd. | Conditions: Spinal Cord Injury, Safety | Phase 2 | Status: NOT_YET_RECRUITING